DK1682177T3 - Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmi - Google Patents
Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmiInfo
- Publication number
- DK1682177T3 DK1682177T3 DK04810417.8T DK04810417T DK1682177T3 DK 1682177 T3 DK1682177 T3 DK 1682177T3 DK 04810417 T DK04810417 T DK 04810417T DK 1682177 T3 DK1682177 T3 DK 1682177T3
- Authority
- DK
- Denmark
- Prior art keywords
- antigen
- antibody
- binding fragment
- antagonist anti
- antagonist
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 title 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 title 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 108010029697 CD40 Ligand Proteins 0.000 abstract 2
- 102100032937 CD40 ligand Human genes 0.000 abstract 2
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010063916 CD40 Antigens Proteins 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000004654 survival pathway Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51733703P | 2003-11-04 | 2003-11-04 | |
| US52557903P | 2003-11-26 | 2003-11-26 | |
| US56571004P | 2004-04-27 | 2004-04-27 | |
| US61179404P | 2004-09-21 | 2004-09-21 | |
| PCT/US2004/036954 WO2005044304A2 (en) | 2003-11-04 | 2004-11-04 | Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1682177T3 true DK1682177T3 (da) | 2010-11-01 |
Family
ID=34577850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04810417.8T DK1682177T3 (da) | 2003-11-04 | 2004-11-04 | Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmi |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070110754A1 (da) |
| EP (2) | EP2243491A1 (da) |
| JP (2) | JP4765037B2 (da) |
| KR (1) | KR20070028295A (da) |
| CN (1) | CN1929862B (da) |
| AT (1) | ATE474598T1 (da) |
| AU (1) | AU2004287480B2 (da) |
| CA (1) | CA2544364A1 (da) |
| CY (1) | CY1110836T1 (da) |
| DE (1) | DE602004028270D1 (da) |
| DK (1) | DK1682177T3 (da) |
| HK (1) | HK1095269A1 (da) |
| IL (1) | IL175393A0 (da) |
| PL (1) | PL1682177T3 (da) |
| PT (1) | PT1682177E (da) |
| SI (1) | SI1682177T1 (da) |
| WO (1) | WO2005044304A2 (da) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE447412T1 (de) * | 2003-11-04 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren |
| JP4810431B2 (ja) * | 2003-11-04 | 2011-11-09 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｂ細胞に関連する癌に対する治療方法 |
| PL1684805T3 (pl) * | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40 |
| PL1680141T3 (pl) * | 2003-11-04 | 2011-04-29 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40 |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| US20050281815A1 (en) * | 2004-02-26 | 2005-12-22 | Dani Eshel | CD40 splice variants and their uses |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| ES2400660T3 (es) * | 2005-11-01 | 2013-04-11 | Novartis Ag | Usos de anticuerpos anti-CD40 |
| JP2009513712A (ja) * | 2005-11-01 | 2009-04-02 | ノバルティス アーゲー | 抗ｃｄ４０抗体の使用 |
| CN100503827C (zh) * | 2006-03-16 | 2009-06-24 | 复旦大学 | 一种乙型肝炎病毒疫苗增效蛋白及其基因 |
| MEP39508A (en) | 2006-04-21 | 2011-02-10 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
| JP5730576B2 (ja) | 2007-11-07 | 2015-06-10 | ジェネンテック， インコーポレイテッド | 抗ｃｄ４０抗体による治療に対するｂ細胞リンパ腫の応答性を評価するための方法及び組成物 |
| CA2758523C (en) | 2009-04-18 | 2019-03-12 | Genentech, Inc. | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| PT2683406T (pt) | 2011-03-11 | 2019-07-08 | Beth Israel Deaconess Medical Ct Inc | Anticorpos anti-cd40 e utilização dos mesmos |
| JP2016011258A (ja) * | 2012-10-26 | 2016-01-21 | 株式会社ペルセウスプロテオミクス | 抗ヒトｃｄ４０モノクローナル抗体及びその利用 |
| CN116063481A (zh) | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | 人源化抗-cd40抗体及其用途 |
| MA44723A (fr) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics Inc | Anticorps agonistes se liant au cd40 humain et leurs utilisations |
| TWI784957B (zh) | 2016-06-20 | 2022-12-01 | 英商克馬伯有限公司 | 免疫細胞介素 |
| EP3806848A2 (en) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| AR117091A1 (es) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
| WO2023278641A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| PT751781E (pt) | 1993-12-23 | 2004-09-30 | Nat Inst Of Health As Repr By | Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas |
| DE69531607T2 (de) | 1994-03-03 | 2004-06-17 | Alexion Pharmaceuticals, Inc., New Haven | Fusionsgene für den inhibitor des terminalen komplements und proteine |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| EP1173589A1 (en) | 1999-04-16 | 2002-01-23 | F. Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| AU2001259215A1 (en) * | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| JP4271440B2 (ja) | 2000-10-02 | 2009-06-03 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ヒト抗ｃｄ４０抗体 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| PL1680141T3 (pl) * | 2003-11-04 | 2011-04-29 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40 |
| JP4810431B2 (ja) * | 2003-11-04 | 2011-11-09 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｂ細胞に関連する癌に対する治療方法 |
| PL1684805T3 (pl) * | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40 |
| US20080057070A1 (en) * | 2004-11-04 | 2008-03-06 | Chiron Corporation | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| JP6039343B2 (ja) | 2012-10-04 | 2016-12-07 | キヤノン株式会社 | 電子機器、電子機器の制御方法、プログラム、記憶媒体 |
-
2004
- 2004-11-04 EP EP10007491A patent/EP2243491A1/en not_active Withdrawn
- 2004-11-04 AT AT04810417T patent/ATE474598T1/de active
- 2004-11-04 JP JP2006538510A patent/JP4765037B2/ja not_active Expired - Fee Related
- 2004-11-04 PT PT04810417T patent/PT1682177E/pt unknown
- 2004-11-04 US US10/577,642 patent/US20070110754A1/en not_active Abandoned
- 2004-11-04 SI SI200431527T patent/SI1682177T1/sl unknown
- 2004-11-04 DE DE602004028270T patent/DE602004028270D1/de active Active
- 2004-11-04 KR KR1020067010901A patent/KR20070028295A/ko active IP Right Grant
- 2004-11-04 EP EP04810417A patent/EP1682177B8/en not_active Not-in-force
- 2004-11-04 CA CA002544364A patent/CA2544364A1/en not_active Abandoned
- 2004-11-04 CN CN2004800397684A patent/CN1929862B/zh not_active Expired - Fee Related
- 2004-11-04 PL PL04810417T patent/PL1682177T3/pl unknown
- 2004-11-04 DK DK04810417.8T patent/DK1682177T3/da active
- 2004-11-04 WO PCT/US2004/036954 patent/WO2005044304A2/en active Application Filing
- 2004-11-04 AU AU2004287480A patent/AU2004287480B2/en not_active Ceased
-
2006
- 2006-05-02 IL IL175393A patent/IL175393A0/en unknown
-
2007
- 2007-01-25 HK HK07100894.0A patent/HK1095269A1/xx not_active IP Right Cessation
-
2010
- 2010-10-18 CY CY20101100928T patent/CY1110836T1/el unknown
-
2011
- 2011-01-17 JP JP2011007386A patent/JP2011116760A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1682177B1 (en) | 2010-07-21 |
| CA2544364A1 (en) | 2005-05-19 |
| AU2004287480A1 (en) | 2005-05-19 |
| CY1110836T1 (el) | 2015-06-10 |
| JP4765037B2 (ja) | 2011-09-07 |
| JP2011116760A (ja) | 2011-06-16 |
| HK1095269A1 (en) | 2007-05-04 |
| WO2005044304A2 (en) | 2005-05-19 |
| PT1682177E (pt) | 2010-11-29 |
| US20070110754A1 (en) | 2007-05-17 |
| CN1929862B (zh) | 2012-02-15 |
| PL1682177T3 (pl) | 2011-03-31 |
| KR20070028295A (ko) | 2007-03-12 |
| SI1682177T1 (sl) | 2010-12-31 |
| DE602004028270D1 (de) | 2010-09-02 |
| EP1682177B8 (en) | 2010-09-01 |
| EP1682177A2 (en) | 2006-07-26 |
| EP2243491A1 (en) | 2010-10-27 |
| AU2004287480B2 (en) | 2011-09-15 |
| IL175393A0 (en) | 2006-09-05 |
| CN1929862A (zh) | 2007-03-14 |
| WO2005044304A3 (en) | 2005-08-25 |
| ATE474598T1 (de) | 2010-08-15 |
| JP2007510664A (ja) | 2007-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1682177T3 (da) | Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmi | |
| WO2005044306A3 (en) | Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection | |
| CY1111011T1 (el) | Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος | |
| CY1110874T1 (el) | Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας | |
| DK1684869T3 (da) | Fremgangsmåde til terapi af B-celle-relaterede cancersygdomme | |
| ATE327004T1 (de) | Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40 | |
| WO2007053661A3 (en) | Uses of anti-cd40 antibodies | |
| PL375041A1 (en) | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors | |
| BRPI0412890B8 (pt) | método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno | |
| DK1624892T3 (da) | Terapeutisk anvendelse af anti-CSI-antistoffer | |
| DOP2006000013A (es) | Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b | |
| JP2009518441A5 (da) | ||
| RU2012136817A (ru) | СПОСОБЫ ЛЕЧЕНИЯ ДИАБЕТА АНТАГОНИСТАМИ Dll4 | |
| WO2006044433A3 (en) | Methods to treat or prevent viral-associated lymphoproliferative disorders | |
| CY1114654T1 (el) | Anti-cd40 μονοκλωνικα αντισωματα ανταγωνιστες και μεθοδοι για την χρηση αυτων |